300 Participants NeededMy employer runs this trial

Elritercept vs Epoetin Alfa for Anemia

(ELRiSE MDS Trial)

Recruiting at 145 trial locations
No Placebo GroupAll trial participants will receive the active study treatment (no placebo)
Pivotal Trial (Near Approval)This treatment is in the last trial phase before FDA approval
Prior Safety DataThis treatment has passed at least one previous human trial

What You Need to Know Before You Apply

What is the purpose of this trial?

The main aim of this study is to assess how elritercept works in lowering the need for RBC (red blood cell) transfusions and how safe elritercept is when compared with epoetin alfa. Other aims are to learn if elritercept improves tiredness as reported by participants without needing RBC transfusion compared with epoetin alfa, the RBC transfusion burden and quality of life compared with epoetin alfa. The study also aims to find out the extent of the immune response to elritercept. The study will also check on the medical problems (safety) of elritercept.

Who Is on the Research Team?

SD

Study Director

Principal Investigator

Takeda

Are You a Good Fit for This Trial?

Timeline for a Trial Participant

Screening

Participants are screened for eligibility to participate in the trial

2-4 weeks

Treatment

Participants receive either elritercept or epoetin alfa to assess efficacy and safety in reducing RBC transfusion needs

24 weeks
Every 4 weeks for elritercept, weekly for epoetin alfa

Follow-up

Participants are monitored for safety and effectiveness after treatment

24 weeks

Extension

Participants may continue to be monitored for long-term outcomes and safety

Up to 48 weeks

What Are the Treatments Tested in This Trial?

Interventions

  • Elritercept
  • Epoetin Alfa

How Is the Trial Designed?

2

Treatment groups

Experimental Treatment

Active Control

Group I: ElriterceptExperimental Treatment1 Intervention
Group II: Epoetin AlfaActive Control1 Intervention

Find a Clinic Near You

Who Is Running the Clinical Trial?

Takeda

Lead Sponsor

Trials
1,255
Recruited
4,219,000+
Dr. Naoyoshi Hirota profile image

Dr. Naoyoshi Hirota

Takeda

Chief Medical Officer since 2020

MD from University of Tokyo

Christophe Weber profile image

Christophe Weber

Takeda

Chief Executive Officer since 2015

PhD in Molecular Biology from Université de Montpellier